PET effectively measures new breast cancer treatments
PET scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended, according to a study in the July issue of the Journal of Nuclear Medicine. Researchers used PET and a specially-developed radioactive compound to image HER2--a protein often associated with aggressive breast cancer--in breast cancer cells before and after treatment aimed at decreasing HER2 expression.
The researchers noted that this molecular imaging methodology could facilitate development of new targeted therapies not only for breast cancer, but also for certain types of ovarian, prostate and lung cancers that may be aggravated due to HER2.
"Obtaining an accurate assessment of the HER2 expression levels in breast cancer tumors is absolutely essential to know whether treatment aimed at reduction of the protein levels in tumor cells is effective," said the study's senior author Jacek Capala, MD, investigator for the radiation oncology branch of the National Cancer Institute (NCI) in Bethesda, Md. "Our study indicates that PET could be a powerful tool both to identify patients who might benefit from targeted molecular therapies and to manage their care by measuring response to treatment. As research into HER2 therapies continues, similar techniques could be developed for other cancers overexpressing different proteins."
The authors noted that a great deal of new research has been focused on developing therapies targeted to HER2. The protein is overexpressed in approximately 20 percent of breast cancers and also in some ovarian, prostate and lung cancers. Tumors that have an overabundance of HER2 protein are more aggressive and more likely to recur than tumors that do not overexpress the protein.
The imaging technique developed in the study could represent a breakthrough in measuring HER2 expression. The conventional method requires biopsies of tumors that have been removed from the body; however, these samples may not represent the overall characteristics of the tumor and may not accurately estimate HER2 expression. Also, there currently are no means to evaluate how long a therapeutic agent takes to affect the targeted tumors and how long the effects last.
In the study, investigators attached the radioactive nuclide flourine-18 to an HER2-binding variant of a small protein known as an Affibody molecule. PET scans can detect the Affibody compound and allow researchers to visualize breast cancer tumors with HER2 protein in mice. The molecules can also be engineered to specifically bind to other targets for cancer diagnosis and therapy.
The researchers implanted human breast cancer cells--expressing either very high or high levels of HER2--under the skin of mice to show that this method of imaging can be used to monitor changes in HER2 expression after treatment. Researchers then intravenously injected the HER2-targeting Affibody compound and performed PET imaging three to five weeks after tumors had formed. Four doses of the drug 17-DMAG were administered, which decreases HER2 expression, spaced 12 hours apart. PET scans were performed before the treatment and after each dose.
Capala and colleagues found that HER2 expression was reduced by 71 percent in mice bearing tumors with very high levels of HER2 protein and by 33 percent in mice bearing tumors with high levels of the protein, compared to the levels measured before treatment and to tumors that did not receive the treatment.
The investigators confirmed their data using established laboratory techniques to determine the concentrations of HER2 proteins in the same tumors after they were removed from the mice.
The researchers noted that this molecular imaging methodology could facilitate development of new targeted therapies not only for breast cancer, but also for certain types of ovarian, prostate and lung cancers that may be aggravated due to HER2.
"Obtaining an accurate assessment of the HER2 expression levels in breast cancer tumors is absolutely essential to know whether treatment aimed at reduction of the protein levels in tumor cells is effective," said the study's senior author Jacek Capala, MD, investigator for the radiation oncology branch of the National Cancer Institute (NCI) in Bethesda, Md. "Our study indicates that PET could be a powerful tool both to identify patients who might benefit from targeted molecular therapies and to manage their care by measuring response to treatment. As research into HER2 therapies continues, similar techniques could be developed for other cancers overexpressing different proteins."
The authors noted that a great deal of new research has been focused on developing therapies targeted to HER2. The protein is overexpressed in approximately 20 percent of breast cancers and also in some ovarian, prostate and lung cancers. Tumors that have an overabundance of HER2 protein are more aggressive and more likely to recur than tumors that do not overexpress the protein.
The imaging technique developed in the study could represent a breakthrough in measuring HER2 expression. The conventional method requires biopsies of tumors that have been removed from the body; however, these samples may not represent the overall characteristics of the tumor and may not accurately estimate HER2 expression. Also, there currently are no means to evaluate how long a therapeutic agent takes to affect the targeted tumors and how long the effects last.
In the study, investigators attached the radioactive nuclide flourine-18 to an HER2-binding variant of a small protein known as an Affibody molecule. PET scans can detect the Affibody compound and allow researchers to visualize breast cancer tumors with HER2 protein in mice. The molecules can also be engineered to specifically bind to other targets for cancer diagnosis and therapy.
The researchers implanted human breast cancer cells--expressing either very high or high levels of HER2--under the skin of mice to show that this method of imaging can be used to monitor changes in HER2 expression after treatment. Researchers then intravenously injected the HER2-targeting Affibody compound and performed PET imaging three to five weeks after tumors had formed. Four doses of the drug 17-DMAG were administered, which decreases HER2 expression, spaced 12 hours apart. PET scans were performed before the treatment and after each dose.
Capala and colleagues found that HER2 expression was reduced by 71 percent in mice bearing tumors with very high levels of HER2 protein and by 33 percent in mice bearing tumors with high levels of the protein, compared to the levels measured before treatment and to tumors that did not receive the treatment.
The investigators confirmed their data using established laboratory techniques to determine the concentrations of HER2 proteins in the same tumors after they were removed from the mice.